Company intelligence / Profile preview

BioGaia AB

Ownership: Public · BIOG.B
Employees: ~225
Development stage: Commercial

Overview

BioGaia has conducted more than 260 clinical studies using their human strains of L. reuteri on approximately 22,000 individuals of all ages. Results have been published in more than 250 articles in scientific journals. Their products have shown efficacy in infant colic, diarrhea prevention, H. pylori infection treatment, and gingivitis treatment[6][3].

Therapeutic areas: OtherGastroenterologyImmunologyInfectious Diseases
Modalities: ProbioticsLive biotherapeutic products
Industry: Biotech

Drug pipeline

13 assets

L. reuteri Prodentis

12 more assets in the full pipeline.

Request access →

Financials

Market cap: $263
Total revenue: $25.9M
Enterprise value: $5.4M

Beyond the preview

Go deeper on BioGaia AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioGaia AB.

Explore the full profile